Rewiring the System: TG Therapeutics Takes Aim at Progressive MS

NEW YORK, NY – October 08, 2026 — For decades, the structural integrity of our healthcare system has been tested by chronic, progressive neuroimmunological diseases. Multiple sclerosis (MS) is perhaps one of the most glaring examples of this systemic strain. It is a disease that slowly dismantles the biological infrastructure of the individual, subsequently removing active citizens from the public square and placing an immense, compounding burden on the state and medical apparatus. However, the scientific narrative is shifting. As the global medical community prepares to convene in Canada for the 10th Joint ACTRIMS-ECTRIMS Meeting (MSToronto2026) later this month, TG Therapeutics is bringing a slate of data that could fundamentally alter the MS treatment paradigm.

The New York-based biotechnology firm recently announced its presentation schedule for the October 21-23 conference, revealing a dual-track strategy. On one front, the company is pushing the boundaries of cellular biology with a late-breaking presentation on an off-the-shelf CAR T-cell therapy for progressive MS. On the other, it is fortifying the commercial and clinical standing of its approved monoclonal antibody, BRIUMVI (ublituximab-xiiy), challenging established market heavyweights by addressing critical gaps in patient experience and long-term efficacy.

The Frontier of Progressive MS: Off-the-Shelf CAR T

Primary progressive multiple sclerosis (PPMS) represents a profound unmet medical need and a structural failure of current pharmacological interventions. Unlike relapsing forms of the disease, progressive MS offers few therapeutic off-ramps; patients face a steady, relentless decline in neurological function. Into this void, TG Therapeutics is introducing azer-cel, an investigational allogeneic CD19-directed CAR T-cell therapy.

Historically, CAR T-cell therapy has been the domain of oncology, utilizing a patient's own modified cells (autologous) to hunt down blood cancers. The TG-Azercel-101 study, however, pivots this aggressive cellular technology toward autoimmune disease. Furthermore, azer-cel is allogeneic—meaning it is derived from healthy donors. This "off-the-shelf" approach bypasses the complex, time-consuming, and expensive manufacturing bottlenecks associated with autologous therapies. If successful, it democratizes access, transforming a bespoke scientific marvel into a scalable public health tool.

Initial clinical results from the Phase 1 study evaluating azer-cel in patients with PPMS will be delivered as a late-breaking oral presentation by Dr. Daniel Ontaneda of the Cleveland Clinic Mellen Center. The scientific community is watching closely. The core hypothesis is that CAR T-cells can cross the blood-brain barrier to effectively deplete rogue B-cells within the central nervous system—a sanctuary site where traditional therapies often fail to reach.

"We are extremely pleased that the first clinical results from our azer-cel program in progressive multiple sclerosis have been selected for a late-breaking oral presentation at MSToronto2026," stated Michael S. Weiss, Chairman and Chief Executive Officer of TG Therapeutics.

Challenging the Blockbusters: Plugging the 'Wearing-Off' Gap

While azer-cel represents the frontier, BRIUMVI represents the company's current commercial anchor. Approved for relapsing forms of MS, BRIUMVI is a glycoengineered anti-CD20 monoclonal antibody designed for efficient B-cell depletion at lower doses. But the market is currently dominated by entrenched blockbusters like Roche's Ocrevus (ocrelizumab) and Novartis's Kesimpta (ofatumumab). To capture market share, a new entrant must do more than match efficacy; it must expose and repair the flaws in the existing standard of care.

One such systemic flaw is the "wearing-off effect." Clinical data indicates that some patients on established anti-CD20 therapies experience a resurgence of MS symptoms toward the end of their dosing cycle. This phenomenon is a biological loophole, potentially driven by premature B-cell repopulation or insufficient depletion in certain tissue compartments.

At MSToronto2026, TG Therapeutics will present highly anticipated data from the ENHANCE study, directly targeting this vulnerability. The presentations will detail how transitioning patients from ocrelizumab to ublituximab mitigates this wearing-off effect. Crucially, the data aims to quantify the biological basis for this clinical improvement, highlighting increased regulatory T cells (Tregs) and decreased inflammatory monocytes following the switch. By demonstrating a more sustained and comprehensive immunological reset, the company is positioning BRIUMVI not merely as an alternative, but as a structural upgrade for patients failing to maintain stability on current regimens.

Seven Years of Data: The Long-Term Economics of Efficacy

In the realm of chronic disease management, short-term victories are insufficient. A therapy must prove its durability over the long arc of a patient's life. To that end, another cornerstone of the company's Toronto agenda is the presentation of seven-year safety and efficacy outcomes for ublituximab in relapsing MS, led by Dr. Bruce Cree from the University of California, San Francisco.

This extended follow-up, stemming from the pivotal ULTIMATE I and II Phase 3 trials, provides a forensic look at the long-term biological economics of continuous B-cell depletion. Clinicians are tasked with a delicate balancing act: maintaining rapid and profound suppression of the inflammatory cascades that cause demyelination, while mitigating the chronic risks of immunosuppression.

Prolonged B-cell depletion carries known systemic risks, including hypogammaglobulinemia (a reduction in crucial immunoglobulins like IgM), serious bacterial and viral infections, and the rare but devastating progressive multifocal leukoencephalopathy (PML). The seven-year data will be heavily scrutinized by drug safety specialists and practicing neurologists to ensure that the cumulative risk profile does not eventually eclipse the neurological benefits. Furthermore, real-world clinical and safety data from the Phase 4 ENABLE study in the U.S. and the 48-week interim results of the European BRILL study will offer vital insights into how the drug performs outside the sterile confines of controlled trials and within the messy reality of routine clinical practice.

Redesigning the Patient Experience

Beyond the cellular mechanics, there is an infrastructural component to MS treatment that often dictates patient adherence and quality of life. Intravenous infusions tie patients to clinical centers, demanding significant time and logistical coordination. TG Therapeutics is utilizing the MSToronto2026 platform to showcase its efforts to streamline this process.

Presentations will evaluate a consolidated single-dose initiation schedule for BRIUMVI, designed to replace the conventional, more burdensome two-step initiation regimen. By reducing the time patients spend in infusion chairs, the company is addressing the logistical friction that burdens both the citizen and the healthcare facility.

Moreover, the company is setting the stage for the next evolution of its franchise: a subcutaneous formulation. Full data from the Phase 1 subcutaneous BRIUMVI program will be presented, signaling a future where patients might self-administer their highly effective disease-modifying therapies at home. This shift from clinic-based infusions to home-based subcutaneous injections represents a profound transfer of agency back to the patient. It is a necessary structural realignment, ensuring that the systems designed to treat chronic illness do not inadvertently monopolize the lives of those they are meant to heal.